After Teva shakeup, Yitzhak Peterburg steps up as chairman

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Amirah Al Idrus (email | Twitter), and we will feature it here at the end of each week.

After Teva shakeup, Yitzhak Peterburg steps up as chairman

Teva ($TEVA), whose board composition has stirred up some recent shareholder activism, has picked its next chairman. And investors pushing for more experienced leadership may be pleased with his resume. Current board member Yitzhak Peterburg will step in Jan. 1 for controversial chairman Phillip Frost, who over the summer announced he'd be leaving his post amid a boardroom revamp. Unlike his predecessor, Peterburg has some experience in the pharma and healthcare spaces: Before joining Teva's board nearly three years ago, he served as the company's VP of global branded products and helmed Clalit Health Services, Israel's leading healthcare provider. More

Yitzhak Peterburg became the new chairman.

Ron Renaud is the new CEO.


> Just a few months after Ron Renaud completed the sale of Idenix to Merck ($MRK) for $3.85 billion, the biotech CEO's vacation is officially over. Instead, he's opening a new chapter in his career--taking the helm at the upstart RaNA in Cambridge, MA, and switching focus from hepatitis C to long noncoding RNA. Story

Biocept ($BIOC) appointed Dr. Veena Singh as medical director. Release

Ocera Therapeutics ($OCRX) promoted Michael Byrnes to chief financial officer. Release

Institut Pasteur appointed Isabelle Buckle as EVP of research applications and industrial partnerships and Pierre Legrain as EVP of academic development and grant office. Release

Qu Biologics welcomed gastroenterologist Dr. Remo Panaccione to its inflammatory bowel disease advisory team. Release

DuPont ($DD) named Matthias Heinzel as president of DuPont nutrition and health. Release

CMC Biologics appointed Joseph Wypych as general manager of its Seattle facility. Release

Intrexon ($XON) announced the appointment of Peter Emtage as vice president of synthetic immunology. Release

Neogen ($NEOG) named Richard Calk as COO. Release

Pronutria appointed Peter Mueller as president of R&D and chief scientific officer. Release

SynGen hired David Hodl, formerly of Becton Dickinson ($BDX), as president of its cell processing business unit. Release

Jeremy Caldwell joined Ardelyx as the company's executive vice president and chief scientific officer. Release

The AVA Group brought on Stefan Krawielitzki as an organic chemistry expert. Release

Aridis Pharmaceuticals appointed Dr. Steven Opal to its scientific advisory board. Release

BioClinica named John Hubbard as its new CEO. Release

Jeffrey Bluestone joined Juno Therapeutics as the company's scientific adviser. Release

Apricus Biosciences appointed Brian Dorsey as its chief development officer. Release

QLT's ($QLTI) chief financial officer, Sukhi Jagpal, has left the company. Release

Dimension Therapeutics, a 2014 Fierce 15 company, named Dr. Eric Crombez as the company's chief medical officer. Release

Idera Pharmaceuticals ($IDRA) hired Vincent Milano as its CEO. Release

Optio Labs brought on Gregg Smith as its CEO. Release

> Proteostasis Therapeutics named Dr. Po-Shun Lee as vice president of clinical development. Release

Foundation Medicine ($FMI) appointed David Daly as chief commercial officer. Release

Osiris Therapeutics ($OSIR) is expanding its management team with the appointment of Adrian Mollo as general counsel and Dr. Jon Hopper as chief medical officer. Release


Teva's ($TEVA) board of directors appointed Dr. Sol Barer, former CEO of Celgene ($CELG), as a director, effective Jan. 1, 2015. Release

Afferent Pharma announces the election of K. Peter Hirth to its board of directors. Release

Pharma Manufacturing

SOHM announced the appointment of G. Michael Bennett as chair of the advisory board team. Release

Animal Health

Jaguar Animal Health has appointed Tim Dotson to head Regulatory Affairs. Release

Medical Devices

Acton, MA-based Cognoptix, developer of an eye test for diagnosing Alzheimer's disease, has appointed Barry Greenberg to its clinical advisory board. Release


Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.